(18) conducted a retrospective study of 156 patients with locally advanced laryngeal/hypopharyngeal squamous cell carcinoma who received neoadjuvant PD-1 inhibitors combined with nab-paclitaxel/cisplatin, reporting an ORR of 88.5% and a pCR rate of 23.1%. Here, PDCD1 is linked to hypopharynx squamous cell carcinoma.